The Prognostic Effect of MAC30 Expression on Patients With Non-Small Cell Lung Cancer Receiving Adjuvant Chemotherapy.
The purpose of this study was to examine the MAC30 expression in non-small cell lung cancer and to evaluate its prognostic value on therapeutic response in patients with non-small cell lung cancer receiving postoperative chemotherapy. Among a total of 218 retrospective Chinese patients with non-small cell lung cancer, 164 patients receiving adjuvant chemotherapy were enrolled in this study. Real-time polymerase chain reaction was performed to confirm the expression of MAC30 messenger RNA in 32 cases of non-small cell lung cancer tumors with the corresponding nontumor lung tissues. The MAC30 protein expression in all specimens was analyzed by immunohistochemical staining. Moreover, we assessed the correlation of MAC30 expression with clinicopathological features, therapeutic response, and survival of patients. Here, we observed the increased expression of MAC30 messenger RNA in patients with non-small cell lung cancer compared to those in control samples. The overexpression of MAC30 was strongly associated with poor tumor differentiation, high tumor-node-metastasis stage, and lymph node metastasis. In addition, we observed that patients with increased MAC30 expression showed gloomy overall survival and disease-free survival. A multivariate analysis explicated that higher MAC30 expression was a valuable independent prognostic factor of poorer tumor differentiation, shorter overall survival, and disease-free survival in patients receiving chemotherapy. MAC30 could be a useful biomarker of tumor differentiation and outcome of patients with non-small cell lung cancer. Overexpression of MAC30 predicts a worse tumor differentiated stage and prognosis in patients with non-small cell lung cancer receiving adjuvant chemotherapy.
1 Department of Respiratory Medicine, Yixing People's Hospital, Affiliated Jiangsu University, Yixing, Jiangsu, China.
Hui
H
Ding
2 Department of Respiratory Medicine, Nanjing Drum Tower Hospital, Affiliated Hospital of Nanjing University Medical School, Nanjing, Jiangsu, China.
Xianhua
X
Gui
3 Department of Integrative Biology and Pharmacology, Medical School, University of Texas Health Science Center at Houston, TX, USA.
Xubo
X
Lin
1 Department of Respiratory Medicine, Yixing People's Hospital, Affiliated Jiangsu University, Yixing, Jiangsu, China.
Ruhua
R
Chen
1 Department of Respiratory Medicine, Yixing People's Hospital, Affiliated Jiangsu University, Yixing, Jiangsu, China.
Tieliang
T
Ma
4 Department of Elder Endocrinology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu, China.
Yunlu
Y
Sheng
2 Department of Respiratory Medicine, Nanjing Drum Tower Hospital, Affiliated Hospital of Nanjing University Medical School, Nanjing, Jiangsu, China.
Hourong
H
Cai
1 Department of Respiratory Medicine, Yixing People's Hospital, Affiliated Jiangsu University, Yixing, Jiangsu, China.
Yan
Y
Fen
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy / Q000235:genetics* / Q000401:mortality* / Q000473:pathology; D017024:Chemotherapy, Adjuvant; D003131:Combined Modality Therapy; D005260:Female; D015870:Gene Expression; D006801:Humans; D007150:Immunohistochemistry; D053208:Kaplan-Meier Estimate; D008175:Lung Neoplasms / Q000188:drug therapy / Q000235:genetics* / Q000401:mortality* / Q000473:pathology; D008297:Male; D008565:Membrane Proteins / Q000235:genetics* / Q000378:metabolism; D008875:Middle Aged; D060787:Neoplasm Grading; D009362:Neoplasm Metastasis; D009367:Neoplasm Staging; D011379:Prognosis; D012333:RNA, Messenger / Q000235:genetics / Q000378:metabolism
D008565:Membrane Proteins; D012333:RNA, Messenger; C516615:TMEM97 protein, human
MAC30; NSCLC; chemotherapy; survival
Med Oncol. 2013 Jun;30(2):544
23535999
Tumour Biol. 2015 Apr;36(4):3043-9
25544708
Med Oncol. 2013 Jun;30(2):533
23512427
J Clin Oncol. 2008 Jul 20;26(21):3552-9
18506026
Oncology. 2006;71(3-4):259-65
17657172
Cell Physiol Biochem. 2014;33(5):1359-68
24853233
Biochem Biophys Res Commun. 2002 Dec 20;299(5):839-46
12470655
Chest. 2009 Sep;136(3):701-709
19318668
Cancer Res. 2014 Jan 1;74(1):309-19
24108744
Oncogene. 2001 Apr 26;20(18):2225-34
11402317
Nat Rev Clin Oncol. 2013 Apr;10(4):235-44
23438759
Cell Growth Differ. 1993 Sep;4(9):715-22
7694637
Histol Histopathol. 2004 Oct;19(4):1021-31
15375745
Med Oncol. 2014 Sep;31(9):154
25108600
Tumour Biol. 2014 Dec;35(12):12679-88
25227663
BMC Cancer. 2007 Dec 11;7:223
18070364
Cancer. 1997 Nov 1;80(9):1803-4
9351551
Nucleic Acids Res. 1999 Feb 1;27(3):839-47
9889281
CA Cancer J Clin. 2008 Mar-Apr;58(2):71-96
18287387
J Thorac Oncol. 2013 Sep;8(9):1128-35
23945383
Tumour Biol. 2015 Sep;36(9):7195-204
25894372
Chemotherapy. 2010;56(6):424-8
21079401
Tumour Biol. 2013 Apr;34(2):821-5
23229099
Int J Oncol. 2007 Jan;30(1):91-5
17143516
Med Oncol. 2013 Mar;30(1):324
23254963
J Clin Oncol. 2010 Jan 1;28(1):35-42
19933916